Expand AGEN Menu
AGEN MENU

AGEN Latest Press Releases

-- August 6, 2026 --

Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer Business Wire 7:30 AM

-- July 28, 2026 --

Agenus to Provide Second Quarter 2026 Financial Report and Development Update Business Wire 4:30 PM

-- July 24, 2026 --

GSK's Shingrix (Recombinant Zoster Vaccine) prefilled syringe presentation approved in Canada PRNewswire 6:50 AM

-- July 17, 2026 --

Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026 Business Wire 10:28 AM

-- July 13, 2026 --

Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer Business Wire 6:00 AM

-- July 6, 2026 --

Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026 Business Wire 7:30 AM

-- June 25, 2026 --

Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026 Business Wire 7:00 AM

-- June 2, 2026 --

Agenus Announces Virtual 2026 Annual Shareholders Meeting Business Wire 4:30 PM

-- May 21, 2026 --

Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026 Business Wire 5:00 PM
Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC Business Wire 5:00 PM

-- May 15, 2026 --

Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer Business Wire 4:11 PM

-- May 11, 2026 --

Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development Business Wire 8:45 AM

-- May 4, 2026 --

Agenus to Provide First Quarter 2026 Financial Report and Corporate Update Business Wire 4:30 PM

-- April 21, 2026 --

Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026 Business Wire 10:00 AM
Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs Business Wire 8:00 AM

-- April 17, 2026 --

Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer Business Wire 4:43 PM

-- April 3, 2026 --

Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026 Business Wire 7:30 AM

-- April 1, 2026 --

Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer Business Wire 7:30 AM

-- March 26, 2026 --

Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access Business Wire 4:52 PM
Market Data Delayed 15 Minutes